Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Wed, October 14, 2026 at 12:02 AM UTC 3 min read

Kura Oncology has announced the launch of a new diabetes venture, backed by $50 million, aimed at developing an oral menin inhibitor. This strategic move diversifies Kura's portfolio and positions the company to tap into the growing diabetes treatment market. For investors, this initiative could enhance long-term growth prospects and potentially increase shareholder value as Kura expands its therapeutic focus beyond oncology.

Read full article →

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Wed, October 7, 2026 at 11:15 AM UTC 3 min read

Caspian Therapeutics and Kura Oncology are set to host an investor webcast to discuss the launch of Caspian's initiatives and present preclinical data on KO-7246, a potential diabetes treatment. This event is significant for investors as it highlights advancements in Kura's pipeline and collaboration with Caspian, which could enhance Kura's market position and attract interest in its innovative therapies. Investors will be keen to assess the implications of the data on future developments and potential commercialization.

Read full article →